CSL Limited (ASX: CSL) shares have been a great place to invest over the last 12 months.
As you can see on the chart below, during this time the biotherapeutics giant's shares have gained almost 14%.
This would have turned a $10,000 investment into $11,400.
This solid return is nothing new for CSL and its shareholders. Over the last 10 years, CSL shares have generated an average total return of 19.4% per annum.
Can CSL shares continue to outperform?
Given the high quality nature of the CSL business, it is no doubt an ASX share that many investors consider as an investment.
But what might a $10,000 investment today look like in a year?
The good news is that one leading broker believes investors could do very well from an investment into CSL shares today.
According to a note out of Morgan Stanley from last week, its analysts have retained their overweight rating with an improved price target of $354.00.
The broker lifted its price target on the belief that CSL's plasma margins could strengthen more than previously expected thanks to a number of favourable tailwinds and its new collection platform. The latter has been designed to yield greater quantities of plasma in less time.
Based on the current CSL share price of $298.32, Morgan Stanley's price target suggests that the company's shares could rise almost 19% over the next 12 months.
The broker is also forecasting a $4.44 per share dividend from CSL in FY 2023, which stretches the total potential return to approximately 20%.
This means that if you were to invest $10,000 into CSL shares, if Morgan Stanley is on the money with its recommendation, your investment would grow to be worth $12,000 by this time next year.
